(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
9 January 2014 (09.01.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/007661 A1

(51) International Patent Classification:
G01N 33/574 (2006.01) *C12N 5/09* (2010.01)
C12N 5/0783 (2010.01) *A61K 38/16* (2006.01)

(21) International Application Number:
PCT/NZ2013/000115

(22) International Filing Date:
3 July 2013 (03.07.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/668,395 5 July 2012 (05.07.2012) US

(71) Applicant: **CALDERA HEALTH LTD.** [NZ/NZ]; PO Box 11664, Ellerslie, Auckland 1542 (NZ).

(72) Inventors: **WATSON, James, Douglas**; 18 Eltham Road, Apartment 3, Kohimarama, Auckland 1071 (NZ). **FORSTER, Richard, Llewellyn, Sydney**; 263 Ostrich Road, Patumahoe, Pukekohe 2679 (NZ).

(74) Agent: **IN-LEGAL LIMITED**; PO Box 8026, The Terrace, Wellington 6143 (NZ).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:


— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2014/007661 A1

(54) Title: METHODS FOR DETERMINING PERSONALIZED TREATMENT COMPOSITIONS FOR PROSTATE CANCER AND BREAST CANCER

FIGURE 7A



(57) Abstract: The present disclosure provides methods for selecting a treatment composition, or therapy, for the treatment of a cancer, such as prostate or breast cancer, in a patient wherein the treatment composition includes administering a combination of at least two components selected from immune cell activating agents, such as GM-CSF, and antigen display enhancing agents, such as ketoconazole. Methods for treating a patient using the selected treatment composition are also provided, together with methods for monitoring the efficacy of the treatment composition during a treatment period.